• About us
    • Profile
    • Management
    • Board
    • Scientific Advisory Board
  • Our Science
    • Strategy
    • Enabling Technologies
    • Product Classes
    • Publications
  • Pipeline
    • Pipeline
    • NidlegyTM
    • Fibromun
    • Darleukin
    • Dodekin
    • Dekavil
    • OncoFAP Radio Conjugates (Imaging)
    • OncoFAP Radio Conjugates (Therapy)
    • OncoFAP-GlyPro-MMAE
    • OncoACP3 (Imaging)
    • OncoACP3 (Therapy)
    • OncoCAIX
  • Press Releases & Media
    • Press Releases
    • Events
    • Media Library
    • Philogen in the news
  • Work with us
    • Careers
    • Partnering
  • Investors
    • Investor Relations
    • Shareholding
    • IPO
    • Press Releases
    • Financial Statements
    • Financial Calendar
    • Internal Dealing
    • Buyback
    • Analyst Coverage
    • Webinars
    • IR Contacts
  • Governance
    • Board of Directors
    • Board of Statutory Auditors
    • Documents & Procedures
    • Shareholders’ Meetings
    • Codice etico e Modello 231
    • Sustainability (ESG)
Governance
Investors
  • About us
    • Profile
    • Management
    • Board
    • Scientific Advisory Board
  • Our Science
    • Strategy
    • Enabling Technologies
    • Product Classes
    • Publications
  • Pipeline
    • Pipeline
    • NidlegyTM
    • Fibromun
    • Darleukin
    • Dodekin
    • Dekavil
    • OncoFAP Radio Conjugates (Imaging)
    • OncoFAP Radio Conjugates (Therapy)
    • OncoFAP-GlyPro-MMAE
    • OncoACP3 (Imaging)
    • OncoACP3 (Therapy)
    • OncoCAIX
  • Press Releases & Media
    • Press Releases
    • Events
    • Philogen in the news
    • Media Library
  • Work with us
    • Careers
    • Partnering

Philogen FY 2024 report on April 2, 2025

Apr 2, 2025 | 2025, Investors, Past Events

Philogen is pleased to invite you to an upcoming webinar on April 2, 2025, at 15:00 GMT | 16:00 CET. Click on the link to register or contact us at IR@philogen.com

Philogen to attend the Swiss Radiopharmacy Day on March 21, 2025

Mar 22, 2025 | 2025, Past Events, Scientific

Our certified radiation protection experts, Dr. Jacqueline Mock and Dr. Sebastian Oehler, will take part and represent Philochem in the Swiss Radiopharmacy Day.

Philogen to attend the ESMO-ImmunoOncology (ESMO-IO) Congress 2024 in Geneva (Switzerland) on December 13, 2024

Mar 22, 2025 | 2024, Past Events, Scientific

Prof. Dario Neri gave a presentation on  “Armed antibodies”  

Philogen to attend the ZKB Investors Event in Lausanne (Switzerland) on December 11, 2024

Mar 22, 2025 | 2024, Investors, Past Events

Prof. Dario Neri gave a presentation entitled: “Radiopharmaceuticals: an emerging class of anticancer drugs”  

Philogen to attend the ZKB Investors Event in Zurich (Switzerland) on December 4, 2024

Mar 22, 2025 | 2024, Investors, Past Events

Prof. Dario Neri gave a presentation entitled: “Radiopharmaceuticals: an emerging class of anticancer drugs”  

Philogen to attend PEGS Europe in Barcelona (Spain) on November 7, 2024

Mar 22, 2025 | 2024, Past Events, Scientific

Prof. Dario Neri gave a presentation entitled: “Antibody-cytokine fusions for cancer therapy: late-stage clinical results”  
« Older Entries

Recent Posts

  • Philogen is pleased to invite you to a webinar with Prof. Dario Neri, taking place today, June 11, at 11:00 ET | 17:00 CET.
  • La controllata Philochem AG ha concesso in licenza i diritti a livello mondiale su OncoACP3, un nuovo agente terapeutico e diagnostico per il trattamento del cancro alla prostata, a RayzeBio, società del gruppo Bristol-Myers Squibb, per un valore fino a 1,35 miliardi di dollari più royalties.
  • Philochem AG Announces the Licensing of Worldwide Rights to OncoACP3, a novel Radiopharmaceutical Therapeutic and Diagnostic Agent targeting Prostate Cancer, to RayzeBio, a Bristol-Myers Squibb Company, for a potential value of up to $1.35bn plus royalties.
  • The MedChem division of the Italian Chemical Society (SCI) awarded two Prizes to Philochem employees: Samuele Cazzamalli (Head of Chemistry) and Sara Puglioli (Research Scientist)
  • Deposito del Verbale dell’Assemblea degli Azionisti

Recent Comments

    Legal

    Privacy Policy

    Privacy Policy / Cookie Policy

      Contacts

    • Follow
    • Follow

    Philogen S.p.A. ©  Piazza La Lizza, 7 | 53100 Siena (SI) – ITALY | Nr. REA: SI-98772 | P.IVA e CF 00893990523 | Cap. Soc. € 5.731.226,64 i.v. | PEC: AFC@pec.philogengroup.it